Biovest International Inc., the subsidiary of Accentia Biopharmaceuticals Inc., USA has submitted the revision request to the US FDA for using the molecular reduction data in the ongoing pivotal phase 3 studies combined with the physical examination and CT scan evidence of gross tumor reduction for sustaining accelerated, provisional sanction of BiovaxID which is the custom-made anti-cancer vaccine for treating the follicular non-Hodgkin’s Lymphoma.

Non-Hodgkin’s Lymphoma – NHL is the cancer of the lymphatic system which entails the kind of white blood cells – WBC known as Lymphocyte. Due to the distinctive chromosomal deviation in the cancer cells in NHL, as low as 1 malignant lymphocytes in 100,000 normal cells could be noticed in the blood by using the molecular test which is known as Polymerase Chain Reaction – PCR. Based on such a susceptible test, the lack of noticeable cancer cells in the blood is referred to as the molecular reduction. The extensive connection among molecular reduction and the length of tumor-free survival has been exhibited using a variety of therapeutic regimens in the prevalence of the clinical studies.

BiovaxID is the foremost instance of the personalized aimed therapeutic which stimulates the immune system for detecting and annihilating only the cancerous B-cell lymphocytes without collateral damage to the normal B-cell lymphocytes or any other cells. BiovaxID also stimulates the development of anti-tumor antibodies and provokes the immune response to cancerous B-lymphocytes, but not to the normal B-lymphocytes. BiovaxID may even provide enduring immuno-surveillance for persistent tumors as an active immuno-therapeutic. The drug is comprised of the tumor-deprived protein linked to KLH and administered with GM-CSF.